beings the CF antibody response to infection with poliomyelitis virus was not necessarily type-specific. With the establishment of a practical CF test, it became necessary to investigate the development and significance of the Type 2 poliomyelitis CF antibody in the monkey and in man. The rapid development of Type 2, CF antibody in cynomolgus monkeys infected by mouth with Type 2 poliomyelitis virus is described separately (7) . The present paper deals with the occurrence, development, persistence, and significance of the Type 2, CF antibody in human beings with special reference to the pattern observed after infection with other types of poliomyelitis virus. Four main groups of individuals were investigated: (a) Patients who were proved to have been infected with Type 1 poliomyelitis virus by recovery and typing of the virus, and in some instances also by the development of homologous neutralizing antibody in increasing titer. Appropriate neutralization tests with Lansing virus indicated that this group of patients had either no preceding or concurrent infection with Type 2 virus. (b) Patients on whom tests for virus were negative, but whose sera showed on neutralization test that they had had no previous or current infection with Type 2 virus. (c) Patients with a clinical diagnosis of poliomyelitis on whom no data had been obtained regarding infection with Type 2 or other types of poliomyelitis virus. (d) Individuals without history of poliomyelitis, in the same general age group as the patients, some bled during the late summer or autumn and others during the winter months. Tests on early acute phase and serial convalescent serum specimens of each of 32 patients provided information on the rapidity of development and persistence of Type 2, CF antibody in patients infected with other types of poliomyelitis virus.
Materials and Methods
Virus.--The MEF1 variant virus adapted to newborn mice (1, 8) , in its 75th to 100th passage in such mice, was used as a source of antigen. The mean titer of the virus of these passages, as determined by intracerebral inoculation into 4-to 5-week-old mice, in groups of 8 to 10 or 20 per dilution, was 5.6 ± 0.274; the incubation period following intracerebral inoculation of 10 -~ dilution of virus into 3-or 4-day-old mice was 2.2 days, and of these injected mice 90 to 100 per cent were paralyzed within48 hours. Tests with antigens prepared from normal brain and from Japanese B and Western equine encephalitis viruses were included as controls.
All the conditions of the tests followed the description already given (2) with exceptions as will be noted.
A,bigens.---Changes in the preparation of the antigen (2) were: (a) the brains of mice sacririced at 48 hours after inoculation, or at a time when 90 to 100 per cent exhibited paralysis, were the source of antigen. (b) In the interests of simplification and expedition, only brain, not spinal cord, was used. Control antigens of normal tissue, Japanese B and Western equine encephalitis viruses also contained brain but no cord. (c) With increase in the number of serial animal passages, the titer of the antigen increased. Instead of a titer of 1: 2 or 1:4, rarely 1:8, to passage 70, from passage 78 to 110, titrations of 7 lots of antigen containing 20 to 150 ml. in each show as follows: Passages 78 to 79, 1:8; 80 to 82, 85 to 94, and 97 to 100, 1: 16, 95 to 96, 97, 101 to 106, 1:32. At such high titers, the antigens were comparable to those of the encephalitis viruses now in general use for their specific diagnosis (9, 10) . With such highly active antigens, however, a "zone" effect was noted, an effect first described by Espana and Hammon (11) for encephalitis viruses and later confirmed in this laboratory and by Lahelle for poliomyelitis antigen (3) . Accordingly, the MEF1 antigens were diluted to no less than 8 and no more than 16 units for use in the tests; as a rule, the desired point was at 1:8, 4-}-, and 1:16, 2-3+. Control antigens were also diluted to contain the same concentration of brain tissue.
Scra from poliomyelitis-convalescent persons, who had been tested with the earlier low titered antigens (2), revealed generally a higher titer on retesting with the more recent high titered reagent. Consequently, although almost ali sera discussed in this communication were originally tested with low titered antigens, they were retested with high titered antigens, and the results recorded here for the sera derived from poliomyelitis patients and normal controis were obtained with 8 to 16 units of antigen. It should be noted, however, that no significant qualitative change in the results was thus obtained, because sera which yielded negative or dubious results with low titered antigen did not become positive in the tests with high titered antigens.
Sera.--In accord with the practice in this laboratory, all human sera were heated for 20 minutes at 60°C. Since the present study is based on comparative results obtained with sera from individuals with or without clinicaliy recognized poliomyelitis, special care was taken to intersperse test and control specimens. Thus, from 25 to 40 different sera were tested at one time for reaction to MEF1 and one or two control antigens, including the usual controls for anticomplementary effects of serum and antigen. In the repeated testing of so many sera 1:4 was used as the first dilution; this was necessitated, first by the smali amount of serum at hand, and second by the fact that fixation with an undiluted serum or 1:2 dihtion of it was of dubious meaning (2). The titer was read as the highest dilution of serum added to the mixture, which yielded a 2+ or greater reaction; when there was a 4+ in one dilution and 0 to lq-in the next, the titer was found by interpolation.
Test.--The procedure, previously described (2), was not changed. As a check on the reproducibility of the titers, positive control sera were added to each series, often positive human sera and always mouse hyperimmune serum. An ample supply of the latter provided enough for many repetitions and the titer was invariably the same; the titers obtained in different tests can therefore be regarded as comparable.
Neutralization Tests.--Qualitative tests, and when necessary quantitative as well for Type 2 neutralizing antibody, were performed in mice using the Lansing strain of virus. In the qualitative tests the mixtures consisted of undiluted serum and 5-fold or 10-fold dilutions of virus, the result being expressed as the neutralization index, which is the control titer divided by the titer of the virus in the serum. A neutralization index of 50 or over was regarded as significant. In the quantitative test the mixtures consisted of serial 4-fold dilutions of serum and 50 LDs0 of virus, the result being expressed as the 50 per cent final serum dilution endpoint. The sera of some of the patients listed in Table I were tested in monkeys for antibody against the strain of virus recovered from the patient's own alimentary tract, and some of these results have already been reported (12) . In one of the patients, Kan., listed in Table I , the recovered Type 1 virus was of insufficient potency for quantitative neutralization tests in monkeys. Since the CF data obtained on this patient made it desirable to determine whether the recovered Type 1 virus was being passively carried or actually caused the disease, neutralization tests were carried out in monkeys, using a Type 1 virus recovered from another patient, Obe., in the same epidemic. Mixtures consisting of serial 4-fold dilutions of serum and 100 PD60 of virus were inoculated into groups of 4 rhesus monkeys, and the 50 per cent serum dilution end-point determined. 128"** 12
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* These )atieuts were tested for homotypic neutralizing antibody and exhibited an increasing titer during convalescence.
0 ffi neutralization index of <50 for undiluted serum. § 0 = < 1:4; see text. U 12 = 1:12 meaning that there was 4-{--fixation at 1:8 and 0 or It at I: 16. ¶ Smi, and Den. viruses not typed. ** Serum dilution protecting 50 per cent of mice against 50 LD~ of virus. :~ 0(0,0) = neutralizing antibody negative in acute phase and 2-week and 4-week serum specimens. § § The neutralizing antibody tests suggest that a Type 2 poliomyelitis virus infection occurred between 4 weeks and 3 months after onset of the clinicaily recognized attack of poliomyelitis.
[]I[ The 2-week and 4-week Lansing antibody titers were about the same as that of the acute phase serum. ¶ ¶ The 2-week and 4-week Lansing antibody titers were about the same as in the 3-month serum; acute phase specimen contained antibody but was lost before titration. *** 0(0,1:22) = neutralizing antibody negative in acute phase and 2-week specimen but positive in titer of 1:22 in 4-week serum, suggesting a superimposed Type 2 poliomyelitis virus infection during convalescence from first attack; the late rise in CF titer is compatible with this assumption.
RESULTS
CF tests were performed on single or multiple serum specimens from 81 patients with a clinical diagnosis of poliomyelitis, and on those from 159 individuals of similar age groups without clinically recognized poliomyelitis. 31 of the poliomyelitis patients were part of a group which was thoroughly investigated in ways described in a previous communication (12) and subsequently also by quantitative neutralization tests with Lansing virus. Since the poliomyelitis viruses recovered from this group of patients were also investigated in the typing program (13) , and since 4 serial serum specimens, from the acute phase to 3 months after onset, were available in each case, the results with these 31 patients are presented separately (group A). In the remaining 50 patients (group B) there was no such detailed information and the available sera were mostly single or two-phase specimens obtained at various intervals after onset.
FINDINGS IN GROUP A POLIOMYELITIS PATIENTS.--
Thirty-five patients were primarily studied in this group, with low titered antigen~ but the results summarized in Table I include only the 31 patients whose sera were tested with optimum antigen. The 4 patients thus excluded were all infected with Type 1 poliomyelitis virus, as determined by virus recovery and development of homologous neutralizing antibody in increasing titer, and they exhibited no evidence of previous or concurrent infection with Type 2 virus. 2 of these 4 developed no significant Type 2, CF antibody; that of one changed from a titer of less than 1:2 in the serum obtained I day after onset to titers of 1:4 at 2 weeks and 4 weeks respectively, and was less than 1:2 again at 3 years after onset; another had titers of 1:8 and 1:4 respectively at 2 weeks and 4 weeks, and less than 1:2 at 3 years after onset.
The procedures used in the attempted recovery of virus from these 31 patients have already been described (12) . 11 of the 13 strains were shown to be of Type 1 (13) and those of patients Smi. and Den. were not typed; however, the failure of these 2 patients to develop neutralizing antibody for the Lansing virus shows that the virus responsible for their infection also was not Type 2. Only 3 of this group of 13 patients were tested for development of homologous antibody; Obe. had a final serum dilution titer of 1:2 in the acute phase specimen and 1:64 in the 3 month convalescent specimen, when tested against his own virus, and Hopk. showed a rise in titer from 1 : 32 in the acute phase serum to 1 : 214-{-in the 3 month specimen, against his own virus. Patient Kan.'s sera tested with the Obe. virus, showed a rise in titer from 1:32 during the acute phase to 1:128 at 3 months after onset."
For a proper interpretation of the significance of the Type 2, CF antibody response in these patients it is not enough to establish that the patient experienced infection with Type 1 poliomyelitis virus, but it is also necessary to know whether or not he might have had a preceding or concurrent infection with a Type 2 poliomyelitis virus. This information was obtained by means of neutralization tests with the Lansing virus. When both the acute phase and 3 month specimens gave negative results in this test the patient was regarded as having had no preceding or concurrent infection with a Type 2 virus. When the acute phase serum neutralized Lansing virus in the qualitative test and significant CF titers were obtained, quantitative tests for Lansing antibody were performed by the serum dilution method on serial specimens to determine whether or not the titer changed in a manner comparable to that observed in tests with the patient's own strain of virus (12) .
The results of these neutralization tests, presented in Table I , show several patterns. There are individuals in whom the Lansing neutralizing antibody titers show no significant difference between the earliest acute phase and 3 month convalescent sera, and it can be concluded that such patients (e.g., Hopk., Col., Wol., Gaff, and Hud.) had been infected with a Type 2 virus in the past, not during the period of their illness. Then there is the patient, e.g. Kau., who has Lansing neutralizing antibody in a titer of 1:32, 3 days after onset and none 3 months after onset; the test, repeated with identical results on two occasions, showed that the Lansing antibody dropped to a Liter of 1:2 at 2 weeks and was absent at 4 weeks after onset (14) . Since this patient's current illness was proved to be due to infection with Type 1 poliomyelitis virus, by recovery of the virus and development of an increasing titer of homotypic neutralizing antibody within 3 months after onset, it appeared possible that a transitory rise in Type 2 neutralizing antibody may occur in some patients infected with Type 1 virus. This question has been studied more extensively by Sabin (14) who obtained further evidence for the occurrence of this transitory response in heterotypic neutralizing antibody. In patients such as Sic. and Pet., in whom the Lansing neutralizing antibody titer is seen to be about 6 times higher at 3 months after onset than in the acute phase, one has difficulty in deciding whether the Type 2 neutralizing antibody response is due to the heterotypic stimulation by the Type 1 virus, which was recovered from their alimentary tract, or to a concurrent infection with a Type 2 virus. The former supposition is perhaps favored by the demonstration, not shown in Table I , that in both patients the titer was somewhat higher at 4 weeks than at 3 months (14) . The data on patients Van., Ten., and Mac., who had no Lansing neutralizing antibodies during the acute phase or 2 weeks after onset, but developed them between the 2nd and 4th week (Mac.) or between the 4th and 12th week (Vau. and Ten.), suggest a dual type of infection separated by an interval of weeks--the second one, presumably due to infection with the Type 2 virus, being clinically inapparent. This assumption gains support from the fact that a marked rise in the Type 2, CF titer occurred in Mac. and Vau. at the same time as the Lansing neutralizing antibody changed from negative to positive. In patient Ten. the CF antibody rise was either missed during the 2 month interval or failed to occur because the first infection with a non-Lansing type of virus called forth a very high titer of Type 2, CF antibody.
It is plain from the data just given that in none of the 31 patients presented in Table I was there evidence that the illness under investigation was caused by a Type 2 poliomyelitis virus, although the majority of them exhibited high titers of Type 2, CF antibody in their acute phase sera or developed such antibody shortly thereafter. Only 4 of the 31 (Obe., Pet., Wol., and Hud.) exhibited a 4-fold or greater difference in titer between the acute phase and 2 week serum specimens. Excepting the 3 patients (Vau., Ten., and Mac), whose Lansing neutralizing antibody data suggest a superimposed infection with Type 2 poliomyelitis virus some weeks after the current illness, there was no further increase in CF titer between the 2week and 4 week specimens. The first serum specimen was obtained within 24 hours of onset of the first fever or symptoms (headache, nausea, sore throat, etc.) in 39 per cent, within 3 days in 74 per cent, and in all 31 patients within 5 days. It is apparent, therefore, that the failure to demonstrate a 4-fold or greater rise in CF antibody in a larger proportion of the patients must be due to the fact that the CF antibody was present in maximum titer very early during the course of infection. The arithmetical mean of the titers during the first 5 days was 1:33 as compared with 1:38 at 2 weeks after onset. The conclusion that in most patients showing no demonstrable increase in titer the CF antibody actually developed during the current illness is based on two considerations (a) the very low incidence of similar titers in the control group, to be described shortly, and (b) the tendency for the CF antibody to disappear or drop in titer at 3 months. Thus, in 2 patients (Smi. and Let.) with peak titers of 1:24 and 1:64 at 1 or 3 days after onset, the titers were 0 (<1:4) at 3 months. A 4-fold or greater drop in titer occurred at 3 months in 9 of 18 patients who exhibited titers of 1:16 or greater during the first 4 weeks (patient Vau. was not con- Table III is based on titers of 1:16 or higher, because titers of this magnitude were encountered only infrequently in the control group, and on the response during the first 2 weeks in order to permit inclusion of the patients with a superimposed infection after that time. In the 13 patients, from whom virus was recovered, there was no difference in response among those who had the paralytic disease and those with a non-paralytic infection; 69 per cent of these 13 patients had titers of 1:16 or over and 54 per cent, titers of 1:32 or over. This does not include one patient (Obe.) who exhibited at least a 4-fold increase in titer, which however did not exceed 1:12. Among the 18 patients with negative tests for virus, all 3 paralytic patients had titers of 1 : 16 or over, while only 40 per cent of those with a diagnosis of non-paralytic poliomyelitis had titers of this magnitude. While the numbers are too small for statistical significance, it is not improbable that some of these patients may have had aseptic meningitis due to some agent other than the virus of poliomyelitis. At any rate it is clear that somewhat more than 70 per cent of patients, infected with non-Lansing strains of poliomyelitis virus, exhibit either a significant rise in heterotypic Type 2, CF antibody or titers of a magnitude only infrequently encountered in controls.
FINdinGS z~ G~ouP B POLIOMYELITIS PATIENTS.--
The patients in this group were not studied as thoroughly as those in group A. Only in 4 were attempts made to isolate the virus from the alimentary tract; from these 4, Type 1 virus was recovered. Of the 50 patients in this group, 39 were paralytic; 7, non-paralytic, and 4 of uncertain type. Their ages ranged from 6 months to 15 years, the greatest number being 1 to 9 years old.
CF Antibody: Development and Persistence.--Two serial serum specimens were obtained from 27 patients of whom 22 were paralytic, 3 non-paralytic, and 2 of uncertain clinical type; the first, 1 to 7 days after onset and the second, from 13 to 82 days after onset, in 20 patients between the 27th and the 35th day. A 4-fold, or greater, rise in titer between the first and second specimens, from a negative finding at 1:4 to positive at 1:12, was observed in only one of these patients. In contrast, the second sample in 5 cases, obtained not later than 35 days after onset, exhibited a 4-fold, or greater, decrease in titer as compared with the first. Table IV contains a summary of the results on 76 serum specimens from the 50 patients; all sera collected within 7 days after onset have been placed under the caption "acute phase;" "convalescent" means those obtained from li to 135 days after onset, i.e. 6, after 11 to 17 days; 27, 25 to 35 days, 10, 44 to 88 days, and 1 after 135 days. These four subgroups show no appreciable difference from one another. Table IV reveals that 75 per cent of the acute phase sera were positive in a dilution of 1:16 or higher, and 62.5 per cent in a dilution of 1:32 or higher. Titers of 1 : 16 or higher were encountered in 63.6 per cent of the convalescent sera, and 1:32 or higher in 43.2 per cent. There is no significant difference in number or titer of positive reactions among the acute and convalescent phase sera. Finally, no comparison could be made of the reaction in relation to clinical type of the disease owing to the smaU number of non-paralytic cases. It is noteworthy, however, that the 75 per cent incidence of titers of 1:16 or higher in the acute phase sera of group B is the same as that encountered during the first 2 weeks in the 8 paralytic patients in group A (Table HI) . * When serial bleedings were available, the highest titer was entered.
CF in Relation to
among the non-paralytic patients is considerably greater than among those with paralysis (8.5 per cent), although the numbers are too small for statistical significance. Since no such difference between paralytic and non-paralytic cases was found in the group A patients from whom virus was recovered~ that observed in the entire group may be due to the fact that a small proportion of the patients with a diagnosis of non-paralytic poliomyelitis might have had aseptic meningitis due to other causes. The 70 per cent incidence of titers of 1:16 or higher among the 47 paralytic patients is remarkably like the 69' per cent incidence of such titers among the 13 patients from whom non-Lansing strains of poliomyelitis virus were recovered. The results are given graphically, but without classification into clinical types, in Fig. 1 , in which it is seen that 52 per cent of the patients (42 of 81) exhibited at one time or another a positive reaction at 1: 32, or higher dilutions of serum, and 67 per cent (54 of 81), at 1:16, or higher. In contrast, control sera, soon to be described, showed only 2.5 per cent (4 of 159) positive CF reaction at a dilution of 1:32, or higher, and 11.3 per cent (18 of 159) at 1:i6, or higher. Persistence of CF Antibody.--Of the 81 patients, 58 yielded the first serum sample within 7 days after onset and the second after from 27 to 60 days (50 of them after 27 to 35 days). Only 5 showed a 4-fold, or greater, titer in the second sample, including 2 in which this had a titer of less than 1:16. A graphic analysis (Fig. 2) was made with respect to the persistence of antibody, in which all the sera studied were grouped in 4 classes according to the time which had elapsed between the onset of disease and the day of serum collection. It follows that in the graph, the same individual is not necessarily represented in all 4 groups. These were divided as follows: 1 to 7 days after onset, 63 sera; 14 days, 43 sera; 28 to 57 days, in 2 subgroups: 28 to 35 days, 52 sera and 3 sera; 90 days, 31 sera, and a single sample of serum at 135 days.
It is clear that the sera of all the groups of patients, except the last, revealed CF reactions of similar pattern: 40 to 45 per cent of those of the 3 groups yielded positive results in 1:32 dilution, or higher, and 55 per cent in 1:16, 100| / C o~: "/-day ~eeum . . . . . Ti~e~ and ovem FIo. 2. As in Fig. 1 except that poliomyelitis sera are in 4 groups with respect to time between onset of disease and day of serum collection; controls, in 2 groups, serum collected in autumn and in winter. or higher. In the remaining group, on the other hand, that of 60 to 135 days, the titers were generally at a somewhat lower level, although the difference could not be proved statistically significant. The titers of this last group were, however, far above the level of those shown by control sera. The arithmetical means of the four groups were: 1 to 7 days, 1:37; 14 days, 1:32; 28 to 35 days, 1:29; and 60 to 135 days, 1:19. What has already been stated to apply to the thoroughly studied group A patients in whom diagnoses were checked by various available means, including virus isolation, can therefore be said with equal weight for the combined group of 81 individuals diagnosed on clinical grounds as having poliomyelitis.
Control Sera.--The following observations were made on sera deriving from persons who gave no evidence of having had poliomyelitis and could therefore serve as controls. It is to be stressed here that Type 2 neutralizing antibody develops with time and becomes widespread among the population of the areas in which the present patients have dwelt, so that by the time the age of 10 to 14 years is reached about 85 per cent of the population have this antibody (16) , and in adults of low-income groups, 100 per cent (17) .
Sera were collected from 159 persons, a single sample from each. It was considered important to obtain specimens at seasons when the incidence of the clinical malady is highest, i.e. late August and September, and also when it is lowest, i.e. January to April. Moreover, it seemed important to have for comparison as many sera as possible in the same age groups as the poliomyelitis patients, namely, from 1 to 19 years. The findings are given in Table VII. There were 127 control sera secured during August to November. The number yielding positive CF reaction in dilution of 1 : 16, or higher, was from 10 to 20 per cent of the total, regardless of the age of the patient.
It has already been shown (18) that there is a changing pattern in the distribution of Type 2 neutralizing antibody in a normal population during the warmer months, that is to say the poliomyelitis season, when about 20 per cent of the early age groups, previously free from neutralizing antibody, acquire it. The dissemination of Type 2 virus might very well have influenced the results of the CF reaction. To what extent it did so was investigated by testing 127 normal sera collected during the warmer months, and 32 during winter and early spring, the non-epidemic period.
The distribution of the results (Table VII) seems to indicate fewer positive reactions and lower titers in non-epidemic than in epidemic seasons. The numbers involved are, however, too small for a statistically significant result;" but on inspection of Table VIII this trend is clearly observed.
On inspection of Table IX one can see no significant difference between the number of positive CF reactions among the sera that had Type 2 neutralizing antibody and those that had none.
Of the control sera, 80 were obtained from apparently healthy individuals and 79 from patients having rheumatic fever, herpangina, or diarrhea. No noteworthy differences were seen in the distribution of CF reactions in the two groups.
Thus, in the present series of control sera, while no statistically significant effect on the results of CF reactions could be referred to age, season, presence of Type 2 neutralizing antibody or certain pathological states of the donors, there appears on inspection to be some relationship to season. This can be seen in Table X in which all the data on control sera have been assembled. 11.3 per cent of the sera showed a positive CF reaction in a dilution of 1:16, or higher, ranging from 3.1 per cent positive, with sera collected in winter, to 13.4 per 
RECAPITULATION
Sera from 81 patients with a diagnosis of paralytic or non-paralytic poliomyelitis and from 159 controls of similar age groups, without history of poliomyelitis, were tested with a high titered, Type 2 (Lansing-like) poliomyelitis, CF antigen derived from newborn mice inoculated with the specially adapted MEF1 strain. Titers of less than 1:4 (original dilution of serum) were regarded as negative. Among 127 controls, bled during the late summer and autumn months, 44 per cent gave positive reactions, 13 per cent having titers of 1:16 or higher, and 3 per cent, titers of 1:32 or higher; among 32 controls, bled during the winter months, 28 per cent gave positive reactions, only 3 per cent had titers of l'16 or higher, and none had titers of 1:32 or higher. Among the poliomyelitis patients, 91 per cent of 47 paralytics gave positive reactions with titers of 1:16 or higher in 70 per cent, and titers of 1:32 or higher in 51 per cent; 77 per cent of 30 non-paralytic patients gave positive reactions, 57 per cent having titers of i: 16 or higher and 47 per cent, titers of 1:32 or higher. Among 13 patients from whom poliomyelitis virus was recovered, there was no difference in CF antibody response between the paralytic and non-paralytic cases.
Among 58 patients, who provided acute phase and convalescent serum specimens, there were only 5 who exhibited a 4-fold or greater increase in titer. There was no evidence of either past or concurrent infection with a Type 2 • poliomyelitis virus in these 5 patients. The occurrence of Type 2, CF antibody and the magnitude of the titer bore no relationship to the presence or absence of neutralizing antibody for Type 2 poliomyelitis virus. Type 1 (Brunhildelike) strains of virus were recovered from 17 of the patients, and the CF resuits obtained on their sera conclusively established the fact that Type 1 poliomyelitis virus can give rise to Type 2, CF antibodies in patients presenting no evidence of previous or concurrent infection with Type 2 virus. The CF antibody was present in peak titers within 24 hours after onset of first symptoms in many patients and, with the 5 exceptions noted above, in almost all of those tested during the first 7 days. Except in 3 cases of superimposed infection with Type 2 virus during convalescence, there were no increases in titer beyond the first 2 weeks. Among 31 patients, who provided sera during the acute phase, at 2 weeks, 4 weeks, and 3 months after onset, there were some (4 of 25) in whom the CF antibody disappeared by 3 months; a 4-fold or greater drop in titer occurred at S months in 9 of 18 patients who had titers of 1:16 or higher during the first 4 weeks.
DISCUSSION
The data here reported establish the fact that human beings who are infected with Type 1 strains of poliomyelitis virus develop CF antibodies for a Type 2 poliomyelitis antigen derived from the variant MEF1 strain especially adapted in newborn mice. In 5 patients, without evidence of either past or concurrent infection with a Type 2 virus, a 4-fold or greater increase in titer of Type 2, CF antibody occurred within 2 weeks after onset of paralytic or non-paralytic poliomyelitis• In the majority of the other patients the CF antibody was found in peak titers within 1 to 5 days after onset of first symptoms, and the evidence that it developed during the course of the current illness was based on the demonstration of both a strikingly higher incidence of positive reactions and of higher titers among the poliomyelitis patients, than those existing among controls with no history of clinically recognized poliomyelitis. Thus, 91.5 per cent of 47 paralytic patients and 76.7 per cent of those diagnosed as having non-paralytic poliomyelitis gave positive CF reac-tions, compared to 44.1 per cent of 127 controls bled during the late summer and autumn months. More striking than the difference in incidence of positive CF reactions was the fact that 67 per cent of 81 poliomyelitis patients fielded titers of 1:16 or greater compared with 13 per cent among 127 summer and autumn controls and 3 per cent among 32 winter controls; 52 per cent of the 81 poliomyelitis patients had titers of 1:32 or greater compared with 3 per cent among the 127 summer and autumn controls and none among the 32 winter controls.
Patients who had no evidence of previous or current infection with Type 2 poliomyelitis virus reacted the same as those giving evidence of past infection, both with regard to incidence of positive reactions and high titers of Type 2, CF antibody. While there were 17 patients from whom Type 1 strains of virus were recovered, and the capacity of Type 1 poliomyelitis virus to stimulate the development of Type 2, CF antibodies in human beings is thus established, no information is available on the effect of Type 3 strains. The rapidity and persistence of the CF antibody response following primary infection with Type 2 virus in human beings are also not known. One of 3 patients of the present series, who developed inapparent Type 2 infection during convalescence, exhibited a rise and fall in Type 2, CF antibody titer comparable to that observed among the other patient~ infected with non-Lansing strains.
Cynomolgus monkeys infected by the oral route with a Type 2 poliomyelitis virus did not yield CF titers of greater magnitude than those found in patients infected with Type 1 virus (7).
Observations on immunized or convalescent monkeys have not thus far revealed a common antigen among the 3 types of poliomyelitis virus (2-6, 13). The present observations on the heterotypic CF antibody response in human beings, and those of Sabin (14) on the transitory appearance of heterotypic neutralizing antibodies, indicate that studies with antigens derived from the Type 1 and Type 3 poliomyelitis viruses will have to be carried out before such data can be properly applied to the diagnosis of human poliomyelitis. Practically applicable serologic methods are most needed in cases of the aseptic meningitis syndrome, and of the "minor illness" or abortive type of disease, in order to establish whether they are caused by infection with poliomyelitis virus. Diagnosis by means of a significant rise in titer between acute phase and convalescent serum specimens occurred too infrequently in tests with Type 2 antigen (only in 5 of 58 cases) to be practically useful, although Svedmyr, Enders, and Holloway (6) have recently reported a significant rise in ,titer in 4 of 7 Type 1 poliomyelitis patients tested with Type 1, CF antigen. Since only 52 per cent of patients with non-paralytic poliomyelitis yielded Type 2, CF titers of 1:16 or greater, it is clear that even a presumptive test based on the magnitude of the titer would fail in about 50 per cent of such patients, when tested only with Type 2 antigen, and a negative result would not signify ab-sence of infection with poliomyelitis virus. Studies, similar to those here reported with Type 2 antigen, carried out with Types 1 and 3, CF antigens should yield information which will indicate how CF reactions in poliomyelitis should be interpreted and to what extent they may be used to diagnose the immunologic type of virus responsible for the infection. It is possible that identification of the type of infecting virus might be achieved more readily by tests for neutralizing antibody in tissue cultures, although here too it will be necessary first to determine the extent of the heterotypic response in human beings.
SUMMARY
Sera from 81 patients with a diagnosis of paralytic or non-paralytic poliomyelitis, and from 159 individuals of similar age groups giving no history of the disease, were tested with a high titered, complement-fixing poliomyelitis antigen of Type 2 (Lansing-like). The antigen consisted of brain tissue from newborn mice injected with the MEF1 strain of virus as previously adapted to these animals. The presence or absence of Type 2 neutralizing antibody in the sera under test was found not to affect the complement fixation.
Positive reactions were obtained with 57 per cent of the sera deriving from non-paralytic patients and in 70 per cent from paralytics, when the specimens were tested at a dilution of 1:16. The complement-fixing antibody was often present in highest titer as early as 24 hours after the onset of poliomyelitis, and in almost all instances within 7 days. In about half of the patients a 4-fold or greater drop in titer occurred within 3 months, with little or no change in the others.
The incidence of titers of 1:16 or higher with the control sera varied with the season of the year at which they were procured, 3 per cent of the winter samples proving positive and 13 per cent of the summer.
The tests of sera from the group of patients from whom poliomyelitis virus was recovered, disclosed no significant differences between those having the paralytic and those having the non-paralytic disease.
Type 1 (Brunhilde-like) strains of virus were recovered from many of the patients yielding positive tests, although they presented no evidence of previous or concurrent infection with Type 2 virus. This finding shows that Type 1 virus can give rise in patients to Type 2 complement-fixing antibody.
The application of these data to the serologic diagnosis of poliomyelitis infection in man will of necessity be limited until information is obtained on the development, persistence, and significance of complement-fixation reactions with antigens deriving from Type 1 and Type 3 poliomyelitis strains. 
